Atricure Inc. Stock
Price
Target price
?
?
-1.650%
-0.4
-1.650%
€43.22
08:05 / Frankfurt
WKN: A0ES9W / Symbol: ATRC / Name: AtriCure / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Atricure Inc. Stock
We can see a decrease in the price for Atricure Inc.. Compared to yesterday it has lost -€0.400 (-1.650%).
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Atricure Inc..
As a result the target price of 43 € shows a very positive potential of 80.67% compared to the current price of 23.8 € for Atricure Inc..
Pros and Cons of Atricure Inc. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | -1.650% | -3.200% | -6.202% | -60.968% | -28.824% | -60.968% | -56.396% |
| SI-BONE Inc | -1.790% | -0.909% | -16.794% | -16.794% | -35.503% | - | - |
| Lantheus Holdings Inc | -0.550% | -0.122% | 3.091% | -27.970% | 14.266% | -14.562% | - |
| Orasure Tech | -0.760% | -3.731% | -3.008% | -16.234% | 25.243% | -51.321% | -73.818% |
Comments
AtriCure (NASDAQ:ATRC) was given a new $55.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (NASDAQ:ATRC) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $54.00 price target on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (NASDAQ:ATRC) had its price target raised by analysts at JPMorgan Chase & Co. from $42.00 to $48.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
News
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
This medical device innovator for cardiac surgery reported an insider sale amid a year of negative total returns.
Doraiswamy Vinayak, Chief Scientific Officer of AtriCure (NASDAQ:ATRC), reported the
Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?
Sven Wehrwein, a member of the Board of Directors at AtriCure (NASDAQ:ATRC), exercised 10,000 non-qualified stock options and immediately sold the underlying shares in derivative transactions on